Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Dilutive issuance
confidence 95%
filed 2026-06-30
Dreamland Limited entered into a securities purchase agreement on June 25, 2026, to issue 380,000 Class A ordinary shares at US$3.75 per share for aggregate gross proceeds of US$1,425,000. The shares were issued in an unregistered offshore transaction to a non-U.S. person under Regulation S, with transfer restrictions and restrictive legends. This is a classic private placement of unregistered equity securities, which is material to investors as it represents dilution and a capital raise.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-06-30
The filing's primary disclosure is the entry into a $1,000,000 Loan Agreement with the Philip & Daniele Barach Family Trust (Item 1.01), creating a direct financial obligation with a 4.0% base interest rate and first-priority security interest in substantially all personal property. While the filing also discloses a board member resignation (Item 5.02), the debt issuance is the material financial event that would affect investor assessment of the company's capital structure and liquidity position.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-30
The filing discloses a private placement (PIPE) of approximately $2,000,000 in unregistered securities, including pre-funded warrants and common stock warrants, closed on June 29, 2026. Item 1.01 describes the Securities Purchase Agreement and Item 3.02 explicitly confirms the unregistered sale under Section 4(a)(2) and Regulation D Rule 506(b). This is a classic dilutive equity issuance raising capital through warrant and equity instruments, material to investors assessing ownership dilution and capital structure.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-06-30
The 6-K discloses results of a General Meeting held on June 30, 2026, where shareholders voted on three proposals: (1) approval of a share consolidation at a ratio between 1-for-4 and 1-for-30, (2) amendment of the memorandum and articles of association to reflect the consolidation, and (3) an adjournment proposal. All three proposals passed with overwhelming majorities (99.81%, 99.88%, and 99.92% respectively). This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and the share consolidation is material to investors as it affects share structure and voting rights.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-30
The filing discloses completion of a material acquisition on June 30, 2026, under Item 2.01. Brand Engagement Network acquired all equity interests of Cataneo GmbH for $19.5 million in cash and stock. The acquisition is material: Cataneo generated €8.6 million in 2025 revenue, manages €6 billion in annual advertising inventory, and serves 1,000+ media brands. The company funded the acquisition through a dilutive equity issuance (250,792 shares at $37.88 per share plus additional common stock and warrants at $39.59 per share), which would materially affect investor assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-06-30
The 6-K discloses execution of the Third Amendment to the Merger Agreement on June 30, 2026, extending the Outside Date for closing of Plutus Financial Group's acquisition of Choco Up Group Holdings Limited from June 30, 2026 to September 30, 2026. This is a material amendment to an ongoing material acquisition transaction that affects the timing and conditions of a significant M&A event.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-30
The filing discloses that Nasdaq previously notified the Company on January 12, 2026, of non-compliance with the $1.00 minimum bid price requirement for continued listing, with a compliance deadline of July 13, 2026. The June 30, 2026 notice confirms the Company has regained compliance and the matter is closed. This is a material delisting-risk event—the Company faced a concrete threat of delisting but successfully remedied the violation before the deadline.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 72%
filed 2026-06-30
Item 2.03
The filing discloses a "Fourth Amendment to Credit Agreement dated June 29, 2026" as Exhibit 10.1. An amendment to a credit facility typically reflects a material modification to the registrant's direct financial obligations—whether extending terms, adjusting covenants, increasing capacity, or restructuring existing debt. The amendment's existence and timing (one day before the 8-K filing) suggests a substantive change to the credit arrangement that would affect investors' assessment of the company's capital structure and liquidity.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
The filing discloses under Item 5.02 the appointment of two new directors to the Board effective June 21, 2026: Ruoxin (Skyler) Wang and Zhang Zhixiang. The prose explicitly states "the Board of Directors...appointed Ruoxin (Skyler) Wang and Zhang Zhixiang as members of the Board, and they accepted their appointments as directors." This is a clear executive appointment event, material to investors as board composition affects governance and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-30
Item 5.02
The filing discloses the election of Paul W. Burkett as a director effective July 1, 2026, with appointment to three Board committees (Audit, Corporate Governance and Nominating, and Transaction Committee). While the section also mentions Michael J. Wartell's resignation, the principal disclosed action centers on the appointment of a new director with significant committee responsibilities. The appointment of an independent director to key governance committees is material to investors' assessment of board composition and oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-30
The filing discloses both the retirement of interim CFO Jeffrey Church (effective July 1, 2026) and the appointment of Josh Blacher as the new interim Chief Financial Officer under a master services agreement with Danforth Health, Inc. While both events occur, the principal disclosed action centers on the appointment of Blacher to the CFO role, with detailed biographical information and compensation terms ($475/hour). The departure of Church is secondary context. This is material as CFO changes affect investor assessment of financial reporting and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-30
The filing discloses the appointment of Andrew Cordell Schaap as a board member effective June 29, 2026, with concurrent appointment to the Audit Committee and Related Party Transactions Committee. While the disclosure also includes a compensatory arrangement (a 200,000-share restricted stock award), the principal disclosed action is the appointment itself. The board expansion from seven to eight members and committee assignments are the core events, making this an exec_appointment rather than exec_compensation.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-30
The filing discloses results of RenovoRx's 2026 annual meeting of stockholders held on June 30, 2026, under Item 5.07. The company reports voting outcomes for three proposals: director elections (six directors elected), approval of a 2021 Plan amendment adding 2,000,000 shares (4.4% of outstanding shares), and ratification of Frank, Rimerman + Co. LLP as independent auditor. These are standard shareholder vote results that materially affect governance and equity structure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-30
Item 5.07
This Item 5.07 disclosure reports the complete voting results from Blink Charging's June 30, 2026 Annual Meeting of Stockholders, including four proposals: election of four directors, approval of a 10,000,000-share increase to the 2018 Incentive Compensation Plan, advisory say-on-pay vote, and ratification of Grant Thornton LLP as independent auditor. The filing presents detailed vote tallies (For, Against, Abstained, Broker Non-Votes) for each proposal, which is the core content of a shareholder vote results disclosure under Item 5.07.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
The filing discloses the appointment of Tomas J. Philipson, Ph.D. to the Board of Directors effective June 26, 2026, along with his concurrent appointment to the Audit Committee and Compensation Committee. While the disclosure also includes compensatory arrangements (equity options totaling 536,428 shares), the principal disclosed action is the appointment of a director with significant government and healthcare economics experience to the board and key committees. This is a material governance event affecting board composition.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-30
The filing discloses Item 5.07 results from Kairos Pharma's June 29, 2026 annual meeting of stockholders, including voting outcomes on five proposals: election of four directors, ratification of auditors (Weinberg & Company, P.A.), approval of a reverse stock split amendment (1:3 to 1:250 ratio at Board discretion), advisory approval of executive compensation, and approval of amendments to the 2023 Equity Incentive Plan (5M additional shares plus 5% evergreen provision). These results are material to investors as they reflect shareholder decisions on governance, capital structure, and equity incentives.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-30
Cycurion entered into an Asset Purchase Agreement on June 24, 2026, to acquire substantially all assets of Kustom Entertainment's video-solutions business, including intellectual property, contracts, customer relationships, and operating assets. The transaction involves aggregate consideration of $1.25M cash, $4.25M secured promissory note, up to $1.0M earnout, and 2M warrant shares. This is a material acquisition disclosed under Item 1.01 that would materially affect investor assessment of the registrant's strategic direction and financial position.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-30
The filing discloses an amendment to a merger agreement dated March 6, 2026 between Non-Invasive Monitoring Systems, Inc., Gravitics Merger Sub, Inc., and Gravitics, Inc. The amendment extends the Outside Termination Date, provides resale registration rights, and revises closing conditions. This constitutes material M&A activity under Item 1.01, as it relates to an ongoing material acquisition/merger transaction.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 85%
filed 2026-06-30
Powerfleet's board authorized a $30 million stock repurchase program over 24 months, disclosed under Item 8.01 (Other Events). Stock repurchases are a form of capital return to shareholders and fall within the dividend_distribution category as a return of capital. The $30 million authorization is material to investors assessing capital allocation strategy and shareholder value, though the program is discretionary and non-binding.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-06-30
Item 8.01
The 8-K discloses Shuttle Pharmaceuticals' acquisition of United Dogecoin Inc., a Dogecoin mining and digital infrastructure company. The press releases (Exhibits 99.1 and 99.2) describe United Dogecoin as "recently acquired by Shuttle Pharmaceutical Holdings, Inc." and detail post-acquisition operational milestones including miner purchases, data centre site acquisition, and infrastructure strategy. This represents a material change of control and business combination that would significantly affect investor assessment of Shuttle's strategic direction and asset base.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 85%
filed 2026-06-30
The Board approved conversion of accrued but unpaid directors' fees totaling $542,500 into Series D-1 Preferred Stock (189,554 shares, convertible to 1,895,540 common shares) at $2.862 per share. This is a compensatory arrangement for directors involving equity issuance in satisfaction of outstanding cash compensation obligations, fitting the exec_compensation category under Item 5.02(e). The materiality is high given the substantial dollar amount and dilutive equity impact.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-06-30
The filing discloses a June 24, 2026 notice from NYSE American indicating InnSuites Hospitality Trust is not in compliance with continued listing standards under Section 1003(a)(i), citing a stockholders' deficit of approximately $(921,921) as of April 30, 2026 and losses in two of three most recent fiscal years. The Trust must submit a compliance plan by July 24, 2026 to regain compliance by December 24, 2027, or face delisting proceedings. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-06-30
Item 1.01
Summit Hotel Properties entered into a $650 million senior unsecured credit facility on June 29, 2026, comprising a $400 million revolving credit facility, a $200 million term loan, and a $50 million delayed draw term loan facility, representing a refinancing of the prior credit facility.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-30
Item 8.01
Akebia announced positive interim analysis results from the VOICE trial demonstrating that Vafseo (vadadustat) met predefined stopping criteria by establishing non-inferiority and superiority on the primary composite endpoint of mortality and hospitalization, with a statistically significant reduction in hospitalizations versus standard-of-care ESA. This represents a material clinical milestone for the company's marketed product, providing significant positive clinical evidence supporting the commercial viability and differentiation of Vafseo in the dialysis anemia market.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
Item 5.02
The filing discloses the appointment of Mark Capone as a Class II director effective July 1, 2026, and his concurrent appointment to the Compensation Committee. The principal disclosed action is a person taking a role on the Board and a Board committee. While the filing also details compensatory arrangements (equity grants and cash compensation), the core event is the appointment itself, making exec_appointment the most salient classification. The appointment of an experienced healthcare executive with 40+ years in diagnostics and prior CEO experience at Myriad Genetics is material to investors assessing the company's governance and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-30
Item 5.02
Nicholas T. Meserve, currently a Managing Director, will transition to the role of CEO in Q4 2026, while incumbent Dwayne L. Hyzak transitions to Executive Chairman. This represents a material executive succession and change in leadership roles.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-30
Item 1.01
The filing discloses entry into a material definitive agreement—the BBCMS 2026-5C42 Pooling and Servicing Agreement dated June 1, 2026—governing a commercial mortgage securitization transaction involving the contribution of two mortgage loans (ONX Industrial Campus and Marriott Savannah Riverfront) and the issuance of BBCMS 2026-5C42 Certificates on June 24, 2026. This constitutes a material acquisition or restructuring of assets within the securitization vehicle, with defined servicing terms and fee arrangements, meeting the Item 1.01 threshold for entry into a material definitive agreement.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-06-30
Item 8.01
This Item 8.01 discloses the issuance of Commercial Mortgage Pass-Through Certificates (BANK5 2026-5YR23) by Morgan Stanley Capital I Inc., representing a creation of new direct financial obligations backed by a pool of 33 commercial, multifamily, and manufactured housing mortgage loans. The filing describes the closing date (July 14, 2026), the multiple certificate classes being issued, the underwriting and purchase agreements, and the prospectus filed with the SEC. While structured as mortgage-backed securities rather than traditional debt, this constitutes a material debt issuance event requiring 8-K disclosure under Item 2.03 principles, though disclosed here under Item 8.01.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-30
EX-99.1
Trinity Biotech announced that its Trinovium subsidiary has secured Silver Membership in the Open Compute Project (OCP), a major industry consortium shaping data center infrastructure standards. This is a strategic operational milestone enabling Trinovium to engage with hyperscale customers and participate in standards development for AI data center liquid cooling—a market projected to grow from $4 billion to $27 billion by 2033. While not a discrete M&A transaction, debt issuance, or earnings event, this represents a material strategic partnership and market-access achievement that would affect a reasonable investor's assessment of Trinity Biotech's ability to commercialize its Trinovium subsidiary and compete in the high-growth liquid cooling sector.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-06-30
Item 8.01
Cal-Maine Foods disclosed a settlement agreement with the U.S. Department of Justice and 17 states' attorneys general resolving antitrust claims following a 15-month DOJ investigation into alleged anticompetitive conduct by egg producers. Although the company denies wrongdoing and was assessed no fines, the settlement requires implementation of compliance measures, donation of 30 million eggs, and payment of $1.5 million to states. This is a material regulatory settlement that would affect a reasonable investor's assessment of the company's legal exposure and operational obligations.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 85%
filed 2026-06-30
Item 8.01
News Corporation discloses daily share repurchase activity under its authorized $1 billion repurchase program, with specific transaction details including 8.76 million Class A shares and 86,681 Class B shares purchased on 30 June 2026 for approximately $220 million in aggregate consideration. Share repurchases are a form of capital return to shareholders and fall within the dividend_distribution category as a return of capital program, distinct from a one-time dividend but functionally similar in distributing value to shareholders.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-30
Item 1.01
Nu-Med Plus entered into a Share Exchange Agreement on June 29, 2026, to acquire 100% ownership of Avid Gold Ltd in exchange for 4,500,000 shares of Series A Preferred Stock and assumption of a $100,000 promissory note, with a required closing date of July 8, 2026. This constitutes a material acquisition and significant change of control, expanding the company's business into gold exploration and development.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 93%
filed 2026-06-30
Item 3.02
Nu-Med Plus issued unregistered Series A Preferred Stock to multiple parties (Hayde, Merrell, and Hock) in consideration for services and as part of the Avid Gold Ltd exchange transaction, with maximum conversion potential of 110 million common shares, representing substantial dilution to existing shareholders under Section 4(a)(2), Rule 506 (Regulation D), and Regulation S exemptions.
View raw filing on EDGAR →
8-K
Governance Other
confidence 73%
filed 2026-06-30
Item 5.03
Nu-Med Plus amended its articles of incorporation to create Series X Super Voting Preferred Stock and Series A Preferred Stock with distinct voting rights and privileges, materially modifying the rights of security holders and altering the company's capital structure and voting power.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-30
Item 8.01
The filing discloses unaudited quarterly financial results for Q2 2026 via a press release issued July 1, 2026, showing 13% revenue growth to $1,247,635 and 30% net income increase to $199,008. This is a standard earnings release disclosure, typically material to investors assessing the registrant's financial performance and operational trajectory.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
Item 5.02
Perrigo appointed two independent directors, Salman Amin and Omer Gajial, to its Board of Directors effective June 30, 2026, increasing board size from 8 to 10 members. Both appointees bring substantial executive experience in consumer products, retail, and digital transformation.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-30
Item 1.01
AquaBounty entered into securities purchase agreements on June 25, 2026, issuing 109,223 shares of Series B Convertible Preferred Stock convertible into 2,184,460 shares of common stock for $2.25 million in a private placement pursuant to Section 4(a)(2) and Regulation D. The unregistered sale to accredited investors represents a significant capital-raising event that will materially dilute existing shareholders upon conversion.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-06-30
Item 3.03
The company established Series B Preferred Stock via a Certificate of Designations filed June 25, 2026, with senior liquidation preferences, an 18% dividend rate, protective provisions requiring two-thirds consent for certain corporate actions, and conversion rights. These modifications materially alter the capital structure and governance rights of existing common stockholders.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
Item 5.02
Guus Franke was appointed Chief Executive Officer by the Board on June 29, 2026, while continuing as Executive Chairman, representing a material executive leadership transition. Jeffrey Jagid transitioned from CEO to President. The appointment reflects the company's strategic evolution as it rebrands to Circle8 Group, Inc.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-06-30
Item 5.03
Atlantic International Corp. changed its corporate name to Circle8 Group, Inc., approved by the Board and filed with Delaware on June 29, 2026, effective immediately, with a corresponding ticker change to CIRC. The name change reflects the company's evolution into a global technology and workforce solutions platform.
View raw filing on EDGAR →
8-K
Cybersecurity Incident
confidence 95%
filed 2026-06-30
Item 8.01
Aflac Japan discovered unauthorized third-party access to its systems between June 15–25, 2026, affecting files containing policy details, personal information, and bank account data. The company engaged third-party cybersecurity experts, notified the Japan Financial Services Agency and affected individuals, and suspended certain systems. This is a material cybersecurity incident requiring disclosure under Item 1.05 (mandatory since 2023) and disclosed here under Item 8.01, with clear potential for legal, reputational, and financial consequences acknowledged in the forward-looking statements.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-06-30
Item 1.01
Pacira entered into a Stock and Asset Purchase Agreement on June 28, 2026, to divest its iovera® business and wholly owned subsidiary Pacira CryoTech to Zimmer Biomet for up to $140 million ($70 million upfront plus up to $70 million in contingent revenue-based milestone payments through 2031), representing approximately 8% of the company's workforce and advancing its strategic transition into a biopharmaceutical company.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-30
Item 8.01
Vistagen announced topline results from the PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder, which failed to achieve its primary endpoint (p=0.427) in the overall population, though post-hoc analysis showed nominal statistical significance in a severe subpopulation. This material clinical development setback for the company's most advanced product candidate was disclosed via press release and conference call.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
Item 5.02
Amanda Cole was appointed as Vice President and Chief Human Resources Officer effective July 21, 2026, reporting to the CEO and overseeing global HR, communications, and EHSQ functions. The appointment also coincided with the retirement of Judith Bacchus from the same role.
View raw filing on EDGAR →
6-K
Earnings release
confidence 85%
filed 2026-06-30
This is a pre-year-end CEO update disclosing FY26 operational and financial performance: gold production guidance met for the 11th consecutive year (1.4–1.5 million ounces), CSA copper mine results, Eva Copper project progress, and record R4.4 billion in shareholder dividends over 12 months. While not a full audited earnings release (the filing notes the financial information has not been reviewed by external auditors), it is a substantive disclosure of annual results and operational metrics that would materially affect a reasonable investor's assessment of the registrant's performance and financial position.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-30
Item 3.02
The Company sold approximately 2.0 million shares of common stock for $29.4 million pursuant to subscription agreements with investors, relying on Section 4(a)(2) and Regulation D exemptions from Securities Act registration. This is a classic unregistered equity issuance to accredited investors under Item 3.02, representing a material capital raise that would dilute existing shareholders and affect the registrant's capitalization.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-06-30
Item 7.01
The Board declared a regular distribution of $9,370,000 (approximately $0.50 per share) to shareholders of record as of June 30, 2026, payable August 17, 2026. This is a straightforward dividend distribution disclosure, material to investors as it affects shareholder returns and capital allocation. The filing explicitly states the distribution amount, per-share amount, record date, and payment date, with an option for reinvestment in company shares.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-06-30
Item 7.01
The filing discloses a declaration of monthly distributions to shareholders across five classes of common shares, with gross distributions of $0.1350 per share payable on or about July 20, 2026. This is a routine but material dividend declaration typical of a real estate investment trust (REIT), affecting shareholder returns and capital allocation.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-06-30
Item 8.01
The filing discloses a declaration of distributions to stockholders across multiple share classes (Class I, D, T, E, and Y common stock) with specific per-share amounts ranging from $0.0343 to $0.0423, payable on or about July 6, 2026. This is a routine but material dividend distribution event typical of real estate investment trusts, which are required to distribute substantially all taxable income to shareholders.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-06-30
Item 7.01
The disclosure explicitly announces a board declaration of a regular distribution of $0.28 per share and a supplemental dividend of $0.05 per share, payable on August 4, 2026. This is a clear dividend distribution event material to shareholders, representing an annualized yield of approximately 9.0%.
View raw filing on EDGAR →